Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
INmune Bio, Inc. stock logo
INMB
INmune Bio
$6.61
+6.3%
$7.48
$4.32
$10.50
$142.96M1.55315,452 shs974,573 shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$0.59
+3.4%
$0.56
$0.34
$3.29
$49.54M1.77531,748 shs987,312 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$5.57
+8.6%
$5.08
$3.13
$26.05
$77.06M2.72306,807 shs505,741 shs
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$0.36
$0.05
$11.78
$5.07M1.2434.54 million shs23.06 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
INmune Bio, Inc. stock logo
INMB
INmune Bio
+6.27%-3.78%-9.45%-14.49%-12.22%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
+3.39%+0.56%+6.39%+6.92%-77.82%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
+8.58%+2.96%+16.77%+19.02%-75.24%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.1272 of 5 stars
3.60.00.00.03.11.70.6
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.2984 of 5 stars
3.54.00.00.00.01.70.6
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.1827 of 5 stars
3.52.00.00.02.81.70.0
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
INmune Bio, Inc. stock logo
INMB
INmune Bio
3.17
Buy$22.80244.93% Upside
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.00
Buy$4.20606.48% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3.00
Buy$62.221,017.10% Upside
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NSTG, JSPR, IPSC, and INMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
5/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/13/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
4/3/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $2.00
3/28/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K15,189.78N/AN/A$1.45 per share4.56
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$114.90M0.45N/AN/A$1.90 per share0.31
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$4.11 per shareN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$127.26M0.00N/AN/A$0.98 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
-$159.54M-$3.53N/AN/AN/A-102.44%-548.25%-53.79%N/A

Latest NSTG, JSPR, IPSC, and INMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million
5/12/2025Q1 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.17-$1.41-$0.24-$1.41N/AN/A
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
3/27/2025Q4 2024
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.54-$0.40+$0.14-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
11.70
11.70
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
4.31
4.31
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
2.73
2.02

Institutional Ownership

CompanyInstitutional Ownership
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A

Insider Ownership

CompanyInsider Ownership
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
5.00%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
4.60%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1022.98 million14.78 millionOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
17086.16 million81.85 millionOptionable
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2015.02 million14.33 millionOptionable
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
55048.12 million46.63 millionOptionable

Recent News About These Companies

Bruker brokers $392M deal for frayed NanoString
NanoString Technologies Inc (NSTG)
Why Is NanoString (NSTG) Stock Up 115% Today?
NanoString Technologies, Inc. (NSTG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$6.61 +0.39 (+6.27%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$6.72 +0.11 (+1.74%)
As of 06/24/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$0.59 +0.02 (+3.39%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$0.58 -0.01 (-1.77%)
As of 06/24/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$5.57 +0.44 (+8.58%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$5.52 -0.06 (-0.99%)
As of 06/24/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

NanoString Technologies stock logo

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.